Somalogic (SLGC) Stock Price
Somalogic Price
Over the last 4 years Somalogic grew revenue by 26.2% annually, reaching 81.72 M USD. For Somalogic, the net margin of -159.5% is up versus -177.1% a few years ago.
Somalogic stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Somalogic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Somalogic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Somalogic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Somalogic Price |
|---|
Somalogic Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Somalogic Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.00 | 55.00 | 81.00 | 97.00 | 81.00 | 98.00 | 116.00 | 143.00 | 170.00 | 205.00 | 245.00 | 292.00 |
| – | 71.88 | 47.27 | 19.75 | -16.49 | 20.99 | 18.37 | 23.28 | 18.88 | 20.59 | 19.51 | 19.18 |
| -53.13 | 60.00 | 59.26 | 55.67 | 40.74 | 40.74 | 40.74 | 40.74 | 40.74 | 40.74 | 40.74 | 40.74 |
| -17.00 | 33.00 | 48.00 | 54.00 | 33.00 | 39.93 | 47.26 | 58.26 | 69.26 | 83.52 | 99.81 | 118.96 |
| -50.00 | -34.00 | -86.00 | -175.00 | -152.00 | -111.00 | -97.00 | -71.00 | -108.00 | -94.00 | -75.00 | -49.00 |
| -156.25 | -61.82 | -106.17 | -180.41 | -187.65 | -113.27 | -83.62 | -49.65 | -63.53 | -45.85 | -30.61 | -16.78 |
| -57.00 | -71.00 | -86.00 | -109.00 | -130.00 | -97.00 | -81.00 | -97.00 | -86.00 | -71.00 | -50.00 | -28.00 |
| – | 24.56 | 21.13 | 26.74 | 19.27 | -25.38 | -16.49 | 19.75 | -11.34 | -17.44 | -29.58 | -44.00 |
| 187.07 | 181.16 | 181.34 | 186.31 | 187.07 | 187.07 | 187.07 | 187.07 | 187.07 | 187.07 | 187.07 | 187.07 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Somalogic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Somalogic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Somalogic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Somalogic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Somalogic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Somalogic stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Somalogic Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Somalogic business model & stock analysis
Somalogic SWOT Analysis
Strengths
Somalogic Inc is known for its cutting-edge technology and expertise in the field of proteomics. The company has developed innovative platforms and tools that enable the measurement of thousands of proteins simultaneously, providing valuable insights for biomedical research and drug discovery.
Somalogic Inc holds a robust intellectual property portfolio, encompassing various patents and proprietary technologies. This not only gives the company a competitive advantage but also serves as a barrier to entry for potential rivals in the market.
Weaknesses
While Somalogic Inc is a recognized leader in proteomics, its market presence is not as widespread compared to some larger competitors. The company may need to invest in marketing and business development initiatives to expand its customer base and increase market share.
Somalogic Inc heavily relies on research funding from academic institutions, government agencies, and pharmaceutical companies. Any decline or interruption in funding sources could pose a risk to the company's financial stability and ongoing research projects.
Opportunities
The field of precision medicine is rapidly evolving, and Somalogic Inc has the opportunity to leverage its advanced proteomic technologies to contribute to personalized diagnostics and treatment approaches. By partnering with healthcare providers and pharmaceutical companies, the company can tap into this growing market segment.
Somalogic Inc can explore opportunities to expand its operations and establish collaborations in international markets. By entering new geographic regions, the company can gain access to a larger customer base, diverse research projects, and potentially untapped sources of funding.
Threats
The market for proteomic technologies is highly competitive, with numerous players offering similar solutions. Somalogic Inc faces the constant challenge of staying ahead of competitors, both in terms of technology advancements and pricing strategies.
The healthcare and biotechnology sectors are subject to strict regulations and compliance requirements. Somalogic Inc must stay updated on regulatory changes and ensure its operations and products meet all necessary standards. Non-compliance could lead to legal issues, reputational damage, and loss of market trust.
Somalogic Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Somalogic Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Somalogic historical P/E ratio, EBIT multiple, and P/S ratio
Somalogic annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Somalogic shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Somalogic stock splits
Somalogic Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 10/5/2023 | Downgrade | BuyHold | 47 | |
| 10/4/2023 | Downgrade | BuyHold | 47 | |
| 9/25/2023 | Downgrade | BuyHold | 59 | |
| 9/24/2023 | Downgrade | BuyHold | 59 | |
| 3/29/2023 | Maintained | Outperform | 60 | |
| 3/29/2023 | Maintained | Buy | – | |
| 3/29/2023 | Maintained | Buy | 59 | |
| 3/28/2023 | Maintained | Outperform | 60 | |
| 3/28/2023 | Maintained | Buy | – | |
| 3/28/2023 | Maintained | Buy | 59 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Somalogic Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/9/2024 | -0.15USD | - | 22.90 MUSD | - | 2024 Q1 |
| 3/26/2024 | -0.16USD | - | 21.47 MUSD | - | 2023 Q4 |
| 11/14/2022 | -0.20USD | - | 20.38 MUSD | - | 2022 Q3 |
Somalogic shareholder structure
| % | Name |
|---|---|
7.05636% | |
6.85052% | |
5.14819% | |
4.75104% | |
4.24336% | |
4.05957% |
Somalogic Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
12.70% | SEC ↗ | |
7.40% | SEC ↗ | |
6.80% | SEC ↗ | |
6.00% | SEC ↗ | |
6.00% | SEC ↗ | |
5.70% | SEC ↗ | |
5.50% | SEC ↗ | |
5.50% | SEC ↗ | |
5.50% | SEC ↗ | |
5.04% | SEC ↗ |
Somalogic Executives and Management Board
15 members · avg. age 57 · 27 % women
Mr. Stephen Williams
Chief Medical Officer
2.55 M USD
Management
Mr. Adam Taich (48)
Interim Chief Executive Officer
Mr. Eliot Lurier (65)
Interim Chief Financial Officer
Ms. Alison Roelke (48)
Chief People Officer
Mr. Ruben Gutierrez (48)
General Counsel
Ms. Lauren Glaser
IR Contact Officer · since 2022
Board of Directors
Mr. Troy Cox (58)
Independent Director · since 2021
Ms. Anne Margulies (67)
Independent Director
Dr. Robert Barchi (76)
Independent Director
Mr. Richard Post (64)
Independent Director
Mr. Eli Casdin (50)
Independent Director
Mr. Jason Ryan (48)
Independent Chairman of the Board
Somalogic Supply Chain
Somalogic Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.79 | 0.73 | — | ||
| 2 | 0.84 | 0.59 | — | ||
| 3 | 0.95 | 0.91 | — | ||
| 4 | 0.92 | 0.78 | — | ||
| 5 | 0.38 | 0.61 | — |
Frequently asked questions about Somalogic
Somalogic Inc represents a set of core values and a corporate philosophy that aligns with its mission. The company is committed to excellence and innovation in the field of protein biomarker discovery. With a focus on transforming healthcare through the power of proteomics, Somalogic Inc strives to develop groundbreaking solutions for early disease detection, personalized medicine, and improved patient outcomes. By leveraging its proprietary SomaScan® Platform, the company aims to provide advanced insights into human health and empower individuals to live longer and healthier lives.
The business model of Somalogic Inc is focused on developing and commercializing precision health tools. They utilize their proprietary SomaScan® technology platform to analyze and measure proteins in the human body. By offering high-quality protein measurement solutions, Somalogic Inc enables advancements in biopharmaceutical research, clinical diagnostics, and personalized medicine. Their innovative approach provides valuable insights into disease detection, monitoring, and therapeutic development. Somalogic Inc's business model aims to revolutionize healthcare by delivering accurate and comprehensive protein data, leading to improved patient outcomes and advancements in the field of precision medicine.
Somalogic Inc is primarily active in the healthcare and biotechnology industries.
The main competitors of Somalogic Inc in the market include companies such as Protagen AG, Biodesix Inc, and Myriad Genetics Inc. These companies operate in the same industry and offer similar products and services as Somalogic Inc. However, Somalogic Inc differentiates itself through its proprietary proteomics technology and innovative solutions. By providing unique and high-quality protein biomarker assays, Somalogic Inc remains positioned as a leading player in the market, enhancing diagnostic and research capabilities for their customers.
Somalogic Inc is a leading biotechnology company specializing in proteomics and molecular diagnostics. Founded in 2000, the company has a rich history of innovation in developing powerful tools to measure proteins. Somalogic's proprietary technology, known as SomaScan®, enables rapid and accurate protein analysis for various applications, including drug discovery, diagnostics, and personalized medicine. With a diverse and talented team of scientists and engineers, Somalogic has forged numerous partnerships with pharmaceutical companies and research institutions to further advance the field of proteomics. Leveraging its expertise and cutting-edge technology, Somalogic Inc continues to make significant contributions to the understanding and treatment of various diseases.
Some significant milestones achieved by Somalogic Inc include pioneering the development of a proprietary proteomics technology called SomaScan, which enables the measurement of thousands of proteins in a single blood sample. The company has also successfully partnered with leading pharmaceutical and biotechnology companies to advance precision medicine and biomarker discovery efforts. In addition, Somalogic Inc has received numerous accolades and recognition for its innovative scientific advancements and contributions to the field of proteomics.
Somalogic Inc is primarily present in the United States.
10 analysts currently rate the Somalogic stock: 7 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Somalogic to generate revenue of 143.16 M USD and earnings per share of -0.52 USD.
The Somalogic share (SLGC) is listed on 3 stock exchanges, including: NASDAQ (SLGC), Frankfurt (76X0.F), München (76X0.MU).
Somalogic Inc is a company specializing in the development and distribution of innovative diagnostic and research products. It was founded in 2000 and is headquartered in Boulder, Colorado. The basic principle of Somalogic Inc is based on the ability to detect and analyze diseases and health conditions through specific molecules in the blood. To do this, the company has developed a unique technology based on the use of special aptamers. Aptamers are short DNA or RNA molecules that can specifically bind to certain proteins. Somalogic has built an extensive library of over 10 trillion aptamers capable of binding to almost all major proteins in the human body. Using these aptamers, Somalogic researchers can analyze more than 5,000 different proteins simultaneously with just a single drop of blood. One of Somalogic's key products is its diagnostic tests. These tests are used to diagnose various diseases or determine the risk for certain health conditions. For example, the company offers tests that can predict the risk of heart disease, cancer, or neurological disorders. Another important part of Somalogic is research and development. The company works closely with various research institutions to gain new insights into the functioning of the human body and potential treatment options. Somalogic relies on close collaboration with its customers and partners to provide tailored solutions and products. In summary, Somalogic Inc is an innovative company that uses state-of-the-art technologies and scientific knowledge to improve global health. The company offers a wide range of products and services that are of great importance for both diagnostics and research and development. Thanks to its unique technology and close collaboration with leading research institutions, Somalogic has already achieved numerous successes. And in the future, the company will continue to play an important role in the medical and healthcare industry.
The expected revenue of Somalogic is 143.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Somalogic is -97.59 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Somalogic at the moment.
The P/S cannot be calculated for Somalogic currently.
The Eulerpool Quality Score for Somalogic is 3/10.
The ISIN of Somalogic is US83444K1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Somalogic is A3C14K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Somalogic is SLGC. The ticker symbol is used to trade Somalogic shares on the stock exchange.
Somalogic is assigned to the 'Health' sector.
The dividends of Somalogic are distributed in USD.
Somalogic stock
Somalogic Peer Group
Somalogic Ticker
Somalogic FIGI
All fundamentals and in-depth analysis of Somalogic
Our stock analysis for Somalogic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Somalogic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.